OphthalLogix Intelligence analyses the gap between what China’s healthcare policies say on paper and what actually happens when those policies reach hospitals, procurement systems, and clinical practice.
Our first intelligence series covers the Chinese intraocular lens (IOL) market — a sector where volume-based procurement, fragmented reimbursement rules, and evolving regulatory classifications create a policy environment that is public in text but private in execution.
We combine frontline clinical insight, primary policy-document analysis, and hospital-system knowledge to produce decision-oriented intelligence. Our editorial standard is simple: if a piece of analysis cannot change a specific commercial, strategic, or investment decision, it does not get published.
OphthalLogix is based in London.
Contact: www.linkedin.com/in/dan-luo-ophthallogix
